{"id":"al001","safety":{"commonSideEffects":[{"rate":null,"effect":"Amyloid-related imaging abnormalities (ARIA)"},{"rate":null,"effect":"Infusion-related reactions"},{"rate":null,"effect":"Headache"}]},"_chembl":{"chemblId":"CHEMBL4650439","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"AL001 binds to TREM2 (triggering receptor expressed on myeloid cells 2) on microglial cells, enhancing their phagocytic capacity and shifting them toward a neuroprotective phenotype. This mechanism aims to reduce neuroinflammation and promote clearance of amyloid-beta and tau pathology in Alzheimer's disease and other neurodegenerative conditions.","oneSentence":"AL001 is a monoclonal antibody that activates TREM2 signaling on microglia to promote neuroinflammatory resolution and clearance of pathogenic proteins in neurodegenerative disease.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:00:25.930Z","_scrapedBy":"cloudflare-swarm","_wikipedia":{"url":"https://en.wikipedia.org/wiki/Lithium_cocrystal","title":"Lithium cocrystal","extract":"Lithium cocrystal  is a form of lithium that combines lithium salicylate and the amino acid L-proline. The ionic cocrystal (ICC) form combines the lithium salt with an organic anion. This formulation allows more of the compound to cross the blood brain barrier and into the central nervous system. The lithium salicylate/L-proline cocrystal allows approximately 20% lower blood serum levels versus lithium carbonate, and thus fewer attendant side effects. The compound is in phase 2 clinical trials for Alzheimer's disease, bipolar disorder, major depressive disorder and PTSD. Lithium cocrystal was created in 2004 at the University of South Florida. It is under development by Alzamend Neuro with the designation AL-001."},"indications":{"approved":[{"name":"Alzheimer's disease (early symptomatic or prodromal stage)"}]},"trialDetails":[{"nctId":"NCT04374136","phase":"PHASE3","title":"A Phase 3 Study to Evaluate Efficacy and Safety of AL001 in Frontotemporal Dementia (INFRONT-3)","status":"TERMINATED","sponsor":"Alector Inc.","startDate":"2020-07-23","conditions":"Frontotemporal Dementia","enrollment":119},{"nctId":"NCT06111014","phase":"PHASE3","title":"Continuation Study for Latozinemab","status":"TERMINATED","sponsor":"Alector Inc.","startDate":"2023-12-08","conditions":"Neurodegenerative Diseases","enrollment":17},{"nctId":"NCT06921590","phase":"PHASE1","title":"A Study to Investigate Lithium Brain/Plasma Pharmacokinetics and Safety of an AL001 Oral Capsule Compared to a Marketed Immediate-release Lithium Carbonate Capsule in Healthy Adult Subjects","status":"ACTIVE_NOT_RECRUITING","sponsor":"Alzamend Neuro, Inc.","startDate":"2025-05-09","conditions":"Pharmacokinetics, Neurology","enrollment":6},{"nctId":"NCT03987295","phase":"PHASE2","title":"A Phase 2 Study to Evaluate Safety of Long-term AL001 Dosing in Frontotemporal Dementia (FTD) Patients (INFRONT-2)","status":"COMPLETED","sponsor":"Alector Inc.","startDate":"2019-09-27","conditions":"Frontotemporal Dementia","enrollment":33},{"nctId":"NCT05053035","phase":"PHASE2","title":"A Phase 2 Study to Evaluate AL001 in C9orf72-Associated ALS","status":"TERMINATED","sponsor":"Alector Inc.","startDate":"2021-09-02","conditions":"Amyotrophic Lateral Sclerosis","enrollment":5},{"nctId":"NCT05363293","phase":"PHASE1, PHASE2","title":"Multiple Ascending Dose Safety, Tolerability, PK Study of AL001 in Alzheimer's Disease Patients & Healthy Adult Subjects","status":"COMPLETED","sponsor":"Alzamend Neuro, Inc.","startDate":"2022-05-04","conditions":"Alzheimer's Disease, Healthy Non-elderly and Elderly Adults","enrollment":65},{"nctId":"NCT06707753","phase":"PHASE1, PHASE2","title":"Safety and Tolerability of AL-001 Ophthalmic Injection in Subjects with WAMD","status":"ACTIVE_NOT_RECRUITING","sponsor":"Beijing Anlong Biopharmaceutical Co., Ltd.","startDate":"2023-09-11","conditions":"Wet Age-related Macular Degeneration (wAMD)","enrollment":21},{"nctId":"NCT06839339","phase":"PHASE2","title":"Efficacy and Safety of AL-001 Ophthalmic Injection in Subjects with WAMD","status":"NOT_YET_RECRUITING","sponsor":"Beijing Anlong Biopharmaceutical Co., Ltd.","startDate":"2025-02-18","conditions":"Wet Age-related Macular Degeneration (wAMD)","enrollment":40},{"nctId":"NCT06718816","phase":"","title":"Long-term Follow-up Study of AL-001 Ophthalmic Injection in Subjects with WAMD","status":"RECRUITING","sponsor":"Beijing Anlong Biopharmaceutical Co., Ltd.","startDate":"2024-12-09","conditions":"Wet Age-related Macular Degeneration (wAMD)","enrollment":21},{"nctId":"NCT05817214","phase":"PHASE2","title":"Cadonilimab Plus Anlotinib for R/M/P Cervical Cancer","status":"RECRUITING","sponsor":"Zhongnan Hospital","startDate":"2023-02-16","conditions":"Cervical Cancer","enrollment":35},{"nctId":"NCT03636204","phase":"PHASE1","title":"A First in Human Study in Healthy Volunteers and in Participants With Frontotemporal Dementia With Granulin (GRN) Mutation","status":"COMPLETED","sponsor":"Alector Inc.","startDate":"2018-09-14","conditions":"Healthy, Frontotemporal Dementia","enrollment":64}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":22,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["lithium salicylate/L-proline cocrystal","Alzamend AL001"],"phase":"phase_3","status":"active","brandName":"AL001","genericName":"AL001","companyName":"Alector Inc.","companyId":"alector-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"AL001 is a monoclonal antibody that activates TREM2 signaling on microglia to promote neuroinflammatory resolution and clearance of pathogenic proteins in neurodegenerative disease. Used for Alzheimer's disease (early symptomatic or prodromal stage).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":4,"withResults":2},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}